Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Free Cash Flow: 2016-2024

Historic Free Cash Flow for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to -$78.3 million.

  • Dianthus Therapeutics' Free Cash Flow fell 43.53% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.6 million, marking a year-over-year decrease of 74.92%. This contributed to the annual value of -$78.3 million for FY2024, which is 111.75% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Free Cash Flow stood at -$78.3 million for FY2024, which was down 111.75% from -$37.0 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Free Cash Flow registered a high of -$29.2 million during FY2022, and its lowest value of -$78.3 million during FY2024.
  • In the last 3 years, Dianthus Therapeutics' Free Cash Flow had a median value of -$37.0 million in 2023 and averaged -$48.2 million.
  • In the last 5 years, Dianthus Therapeutics' Free Cash Flow soared by 51.95% in 2022 and then plummeted by 111.75% in 2024.
  • Dianthus Therapeutics' Free Cash Flow (Yearly) stood at -$64.4 million in 2020, then climbed by 5.63% to -$60.8 million in 2021, then surged by 51.95% to -$29.2 million in 2022, then dropped by 26.57% to -$37.0 million in 2023, then slumped by 111.75% to -$78.3 million in 2024.